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Purpose. The objective of this study is to report a case of a rare, highly lethal tumor, extrarenal malignant rhabdoid tumor (EMRT)
in a 43-year-old man who initially presented with a local recurrence and is now continuously disease free 14 years after aggressive
surgical treatment. The case and literature are discussed.
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1. INTRODUCTION
Malignant rhabdoid tumor (MRT) was ﬁrst described as a
rhabdomyosarcomatous subtype of Wilm’s tumor [1]. Ma-
lignant rhabdoid tumors were recognized as a distinct entity
in 1981 with extrarenal variants now reported in the CNS,
liver, female genital tract, and soft tissues. Extrarenal malig-
nant rhabdoid tumor is a highly lethal, rare tumor with a
poor prognosis. A recent report of extracranial, extrarenal
rhabdoidtumorsestimatedathree-yearsurvivalof9%(stan-
darddeviation6%)andanincidenceof0.15permillionchil-
dren under the age of 15 [2]. The incidence of MRT in adults
is likely lower as cases in adults are less frequently reported.
The medical literature is replete with papers describing the
highly lethal nature of MRT; however, there are reports of
longer survivals that range from 72 to 192 months [3–8]. We
describe a man with a locally recurrent inguinal malignant
rhabdoid tumor diagnosed at age 43 who is continuously
disease-free after 14 years. The combination of this patient’s
age at diagnosis and long survival time following a local re-
currence make this case unique.
2. CASE REPORT
A 43-year-old man presented with left groin pain, and four
months later underwent left herniorrhaphy for presumed in-
guinal hernia during which a 3.5cm mass was found. The
mass was resected during the herniorrhaphy and diagnosed
as an extrarenal malignant rhabdoid tumor. After discussion
atourinstitution’stumorboard,thepatientwasscheduledto
undergo 6 rounds of neoadjuvant chemotherapy which in-
cluded ifosfamide (1.8g/m2 × 5 days), VP-16 (100 mg/m2 ×
5 days), and G-CSF (390µgS Qd a i l y× 20 days) followed
by surgical excision. After two rounds of chemotherapy and
three months after the initial resection, a 3cm ﬁrm, ﬁxed,
subcutaneous mass was palpated on the medial aspect of the
inguinal incision. CT conﬁrmed the presence of a locally re-
current mass not observed on the previous CT exam per-
formed immediately postresection (Figure 1).
2.1. Localexcision
The patient then underwent a wide local excision of
the 3.0cm mass, including the abdominal wall, inguinal
canal, and testicle, combined with lymph node dissection.
Smaller, palpable nodules within the subcutaneous tissue
were present. As he had previously had a herniorrhaphy, an
aggressive resection of the entire tumor bed was performed.
The inguinal canal, left spermatic cord, testicle, and LLQ ab-
dominal wall were removed en bloc. Marlex mesh was used
to reconstruct the defect, and extra iliac lymph node dissec-
tion was performed. Upon pathological evaluation, the tu-
mor was markedly inﬁltrative at the edges although the sur-
gical margins were negative and removed lymph nodes were2 Sarcoma
Figure 1:Roundregionofheterogeneouslyincreaseddensityinan-
terior abdominal wall just superior to symphysis pubis. This region
measures approximately 3cm in diameter. Postoperative inﬂamma-
tory changes are noted just inferior to this region.
Figure 2: Rhabdoid cells grow in loosely cohesive sheets. The cells
are rounded to ovoid, have rounded nuclei with prominent nucle-
oli; homogeneous, deeply, eosinophilic hyaline cytoplasmic inclu-
sions displace the nucleus laterally (hematoxylin and eosin stain, X
600). A magniﬁed part by electron microscopy shows that paranu-
clear spherical aggregates of intermediate ﬁlaments displace most
organelles and the nucleus. No tonoﬁlaments are present (original
magniﬁcation is X 9660).
free of tumor. The tumor extended into the actual substance
of the upper end of the spermatic cord, but not into the testis
or lower end of the spermatic cord.
2.2. Histology
Thecellswereuniformandarrangedinsolidsheets,inﬁltrat-
ing nests, and cords. The nuclei were oval to round with clear
chromatin and a single prominent central nucleolus. The cy-
toplasm was amphophilic to eosinophilic. In many cells, the
nucleus was eccentric, displaced by a bright eosinophilic cy-
toplasmic inclusion. The tumor had brisk mitotic activity
(Figure 2). There were no areas of necrosis. By immunoper-
oxidase stains, the cytoplasmic inclusions were strongly reac-
tive for vimentin. The tumor cells were also positive for cy-
tokeratin and epithelial membrane antigen. They were non-
reactive for leukocyte common antigen and S100 protein.
Mucicarmine stain was also negative.
2.3. Electronmicroscopy
Electron photomicrographs demonstrated neoplastic cells
characterized by enlarged nuclei, prominent nucleoli, and ir-
regular nuclear membrane. There were large whorls of inter-
mediateﬁlamentsformingaggregatesadjacenttothenucleus
(Figure 2).Ultrastructuralelementssuchasdesmosomes,in-
tracellular lumen formation, tonoﬁlaments, thin and thick
ﬁlaments, neurosecretory granules, and cell processes were
not observed.
2.4. Radiationtherapy
Following the operation, the patient underwent external
beam radiation treatment and received 6720 cGy in 56 frac-
tions over 40 days with cone-down technique.
2.5. Followupstatus
As of January, 2007, the patient is continuously disease free
fourteen years after treatment.
3. DISCUSSION
Rhabdoid tumors are characterized by cells with vesicular
nuclei, large nucleoli, and variably prominent eosinophilic
hyaline cytoplasmic inclusions. Ultrastructurally, the latter
consist of whorls of intermediate ﬁlaments. This “rhabdoid
phenotype” may be present focally in a large variety of other
mesenchymal and epithelial malignancies. Tumors in which
speciﬁc lines of diﬀerentiation can be determined should not
be designated as rhabdoid tumors, but should be classiﬁed
accordingtothespeciﬁclineobserved,suchassquamouscar-
cinoma, malignant melanoma, and synovial sarcoma, with
rhabdoid features. The rhabdoid phenotype is usually as-
sociated with a worse prognosis; nevertheless, these tumors
should be classiﬁed and treated according to the speciﬁc
line of diﬀerentiation observed. Such tumors predominate in
adults. Therefore, the diagnosis of malignant rhabdoid tu-
mor is a diagnosis of exclusion, after other possibilities have
been excluded through adequate sampling, ultrastructural,
and immunohistochemical studies. After such tumors with
“rhabdoid phenotype” have been excluded, there is a group
of malignant rhabdoid tumors in the soft tissues that pre-
dominatesininfantsandchildren;however,theoverallrange
is wide and they can also occur in adults.
Histologic diagnosis of extrarenal MRT is aided by a va-
riety of immunostains. Indeed, as observed in our case, these
tumors display polyphenotypic immunohistochemical pro-
ﬁles. A variety of antigens may be detected in the cells of
“pure” extrarenal MRT, including epithelial, mesenchymal,
and neural antigens. The rhabdoid cells are characterized by
aggregates of intermediate ﬁlaments comprised of vimentin
and cytokeratin [9]. A study of eighteen soft tissue MRTs
showed that 94% were positive for vimentin and 59% forRyan Horazdovsky et al. 3
pancytokeratin [10]. The keratin proﬁle is more restricted
than that of epithelioid sarcoma as no tonoﬁlaments are
identiﬁed in MRT by electron microscopy. The immunopro-
ﬁle of extrarenal MRT overlaps that of the so-called “proxi-
mal epithelioid sarcoma.” Existence of the latter as a clinico-
pathologic entity has been questioned; some authors believe
that it represents a variant of extrarenal MRT. Interestingly,
some examples of classic epithelioid sarcoma display aberra-
tions of 22q similar to those described for extrarenal MRT.
The large cell size and marked cytologic atypia associated
with the so-called “proximal epithelioid sarcoma” were not
seen in our case.
Loss of immunoreactivity for INI1 antibody is valuable
in conﬁrming the diagnosis of renal or extrarenal MRT ver-
sus other tumors with focal rhabdoid appearance [11]. INI1
is part of an ATP-dependent chromatin remodeling com-
plex expressed in all tissues [12, 13]. INI1 is a product of
the hSNF5/INI1 tumor suppressor gene that is frequently
mutated or deleted in MRTs. Cytogenetic study of malig-
nant rhabdoid tumors (renal and extrarenal) reveals a re-
gion of common deletion at 22q11, reputedly the locus of
hSNF5/INI1. Analysis of chromosome 22q has recently been
used as an aid to the diagnosis of rhabdoid tumors [14]. In
MRT cell lines, reexpression of the hSNF5 gene induces G1
cell cycle arrest and activation of senescence-associated pro-
teins [15–18].
In a recent study, 6 of 38 cases of MRT retained im-
munohistochemical expression of INI1 and failed to show
any genetic alteration at the hSNF5/INI1 locus. After exclud-
ing other diagnoses, their morphology and combined mes-
enchymal and epithelial patterns were strongly indicative of
thegenuinerhabdoidnatureofthesetumors.Therefore,mu-
tations involving other members of the chromatin remodel-
ing complex may result in functional consequences similar
to hSNF5/INI1 loss of function [19]. Indeed, Fruhwald et
al. reported recently a family with MRT aﬀecting 2 siblings
without hSNF5/INI1 germline mutations, suggesting the ex-
istence of a second predisposing locus for MRT [20]. Unfor-
tunately,nocytogeneticstudywasperformedinourcaseand
no cryopreserved tissue is available for molecular analysis.
Common treatment protocols have been attempted for
rhabdoid tumors and Wilms’ tumor. The British UKW2 and
UKW3 WILMS’ tumor treatment protocols were employed
in 21 patients with renal rhabdoid tumors reported to the
National Registry of Childhood Tumors (NRCT) between
1987 and 1999. The chemotherapy regimen recommended
consisted of vincristine 1.5mg/m2 weekly ×11, then every 3
weeks, together with actinomycin D 1.5mg/m2 and doxoru-
bicin 30mg/mg/m2 given at 3-week intervals for a total of 1
year.Patients with abdominal stage III tumors were to receive
30 Gy radiotherapy to the ﬂank. Median age at diagnosis in
this group was 1.7 years with a 5-year survival of 35% [2].
Other chemotherapy regimes for MRT have included
combinations of cisplatinum, cyclophosphamide, adri-
amycin, and VP-16 [21–23]. The German Society of Pe-
diatric Oncology Protocol consisted of HIT, procarbazine,
ifosfamide, VP-16, methotrexate, cytosine-arabinoside, and
cisplatin [21]. These protocols were reported after our pa-
tient was treated. Unfortunately, most of them are based on
anecdotal reports. Limited clinical trial data exists for ex-
trarenal MRT. Historically, extrarenal MRT has been shown
to be highly lethal with survival near 9% at 3 years [2]. We
attempted neoadjuvant chemotherapy in our patient with
agents known to have eﬃcacy in sarcomas. Despite this, his
disease relapsed while on treatment. An aggressive surgical
excision was then performed along with radiation therapy in
an attempt to eradicate his localized disease. Our experience
demonstrates that despite the extremely poor prognosis as-
sociated with extrarenal MRT, an aggressive surgical excision
and radiation therapy in the setting of localized disease can
result in long-term survival.
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